AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 212 min read

Quarterly profit at clinical research firm Medpace rose to $137.5 million

Medpace reported Q3 2026 revenue of $716.0M, up 8.5% YoY, with net income of $137.5M, or $4.84 per diluted share. EBITDA rose 16.0% to $172.1M. The company also announced a new stock repurchase authorization.

Original reporting
stocktitan.net
Published Oct 21, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MEDP
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Med
01

Why it matters

The earnings release provides fresh financial data that can affect short-term trading decisions.

02

Market read

First earnings report of the quarter, offering new data for traders.

03

What to watch

Potential headwinds from regulatory changes or contract renewals not disclosed in the release.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Medpace is a global contract research organization providing clinical development services to pharma and biotech firms.

Market effects

Sector

Strong earnings may boost sentiment for the clinical CRO sector.

Regional

Positive for US biotech and healthcare services stocks.

Global

Limited to investors tracking US-listed CROs.

Counterpoint

What could challenge this read

If guidance falls short of expectations, the stock could face a pullback despite the earnings beat.

Key entities

  • Company
    Medpace

    Clinical contract research organization reporting Q3 2026 results.

Read at source← All news

Related articles

OCT 21
$MEDPHighAI 8/10

Medpace in the spotlight: Can earnings sustain bookings momentum?

Medpace Holdings Inc. reports Q3 earnings with analysts expecting $4.44 EPS on $714.47M revenue, up from Q2. The company trades at $622.43 with a market cap of $17.4B. Analysts have a neutral consensus rating and a mean price target of $595.92. Investors will watch bookings momentum and backlog growth, which stood at $3.01B in Q2. Medpace's premium valuation and AI disruption are also key concerns.

investing.com2 min
JUL 24
$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

rttnews.com7 min